Crystalline form of a reverse transcriptase inhibitor

The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type- 1 (HIV -1) and type-2 (HIV -2), have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). HIV seropositive individuals are initially asy...

Full description

Saved in:
Bibliographic Details
Main Author MAGUIRE COURTNEY K
Format Patent
LanguageEnglish
Published 03.06.2015
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type- 1 (HIV -1) and type-2 (HIV -2), have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression which makes them highly susceptible to debilitating and ultimately fatal opportunistic infections. The invention is directed to a novel crystalline form of the RT inhibitor 3-chloro-5-({1-[( 4-methyl-5 -oxo-4,5 -dihydro-1H -1,2, 4-triazol-3 -yl)methyl]-2-oxo-4-( trifluoromethy 1 )-1,2-dihydropyridin-3 -yl) oxy )benzonitrile used in the treatment HIV infection and AIDS.
Bibliography:Application Number: CN201380050220